This article is more than 5 years old. Information may no longer be current.

FDA clears Optovue’s epi-mapping software

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Optovue’s epithelial thickness mapping software has become the first to be cleared by the FDA for quantitative measurements of the epithelial and stromal layers of the cornea, according to a company press release.

Aiding in the diagnosis, documentation and management of ocular health and diseases, epi-mapping provides epithelial thickness information in a fast, non-contact exam, the release said. It is available through the iVue and iFusion OCT systems.

“Our epi-mapping software has been the subject of more than 200 publications, underscoring its importance and value in the care of patients with corneal and ocular surface conditions,” Jay Wei, Optovue founder and CEO, said in the release. “With epi-mapping, physicians are able to quantify epithelial thickness in patients in a manner that is suitable for daily clinical practice.”